Peter B. Leone

Biography

Mr. Leone is an experienced executive and hands on manager with over 25 years in life sciences including building four venture capital backed companies as CEO or COO and closing twenty-three strategic corporate agreements cumulatively valued at nearly $900M.  He currently focuses on Business Development, Program Management, and strategic assessment of current and potential pipeline candidates.   Previously at Arrowhead, Mr. Leone helped build new development functions including Manufacturing (CMC) Operations and Clinical Operations. Before Arrowhead, Mr. Leone was COO of Mersana Therapeutics, where he oversaw IND preparations and launched clinical trials for two cancer compounds.  With the first-time CEO, he raised $38M and co-led negotiations for a $334M preclinical stage collaboration with Teva Pharmaceuticals.  Before Mersana, he was CEO at Phenome Sciences, where he established two strategic collaborations with Janssen and Kyowa Hakko. Mr. Leone also was a founder and President at DigiTrace Care Services, which topped $100M revenue before its acquisition.  Before DigiTrace, Mr. Leone grew to partner at Corporate Decisions, Inc. (a Bain spin off now part of Mercer), where he led a multi-year project with Sandoz to launch a first-in-class anti-psychotic Clozaril® (clozapine). Mr. Leone has an MBA from Stanford University and a cum laude degree in Engineering Sciences with pre-med courses from Dartmouth College.  His first professional work experiences were in marketing with Procter & Gamble and engineering with General Electric Mr. Leone is an experienced executive and hands on manager with over 25 years in life sciences including building four venture capital backed companies as CEO or COO and closing twenty-three strategic corporate agreements cumulatively valued at nearly $900M.  He currently focuses on Business Development, Program Management, and strategic assessment of current and potential pipeline candidates.   Previously at Arrowhead, Mr. Leone helped build new development functions including Manufacturing (CMC) Operations and Clinical Operations. Before Arrowhead, Mr. Leone was COO of Mersana Therapeutics, where he oversaw IND preparations and launched clinical trials for two cancer compounds.  With the first-time CEO, he raised $38M and co-led negotiations for a $334M preclinical stage collaboration with Teva Pharmaceuticals.  Before Mersana, he was CEO at Phenome Sciences, where he established two strategic collaborations with Janssen and Kyowa Hakko. Mr. Leone also was a founder and President at DigiTrace Care Services, which topped $100M revenue before its acquisition.  Before DigiTrace, Mr. Leone grew to partner at Corporate Decisions, Inc. (a Bain spin off now part of Mercer), where he led a multi-year project with Sandoz to launch a first-in-class anti-psychotic Clozaril® (clozapine). Mr. Leone has an MBA from Stanford University and a cum laude degree in Engineering Sciences with pre-med courses from Dartmouth College.  His first professional work experiences were in marketing with Procter & Gamble and engineering with General Electric

Research Interest

business and management